

TO THE U.S. PATENT & TRADEMARK OFFICE

Please stamp the date of receipt of the following document(s) and return this card to us

**RE: Response to Office Action/Amendment for METHODS FOR
MODULATING AN INFLAMMATORY RESPONSE**

TITLE OF DOCUMENT(S):

- Transmittal
- Applicant Initiated Interview Request Form
- Continuation Sheet
- Declaration Draft
- Receipt Acknowledgement Postcard

Application No. 10/768,744

File No. 120-000220US

Date Mailed January 27, 2010

Atty/Secty. SML:sjj



QUINE INTELLECTUAL
PROPERTY LAW GROUP P.C.
2033 CLEMENT AVE. STE 200
ALAMEDA CA, 94501

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/768,744
Filing Date	February 2, 2004
First Named Inventor	Christopher A. Hunter
Group Art Unit	1647
Examiner Name	Cherie Michelle Woodward
Total Number of Pages in This Submission	120-000220US

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> PTO-1449 Form	<input checked="" type="checkbox"/> Applicant Initiated Interview Request Form
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Cited References	<input type="checkbox"/> Request for Continued Examination (RCE)
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Copy of PCT Search Report	<input type="checkbox"/> Request for Corrected Filing receipt
<input type="checkbox"/> Amendment and Request for Reconsideration	<input type="checkbox"/> Copy of EP Search Report	<input type="checkbox"/> Copy of Filing Receipt – marked up
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> Replacement Application Data Entry Form
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Additional Enclosure(s) (please identify below):
<input checked="" type="checkbox"/> Receipt Acknowledgement Postcard	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Continuation sheet; Declaration draft
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Authorization to Charge Deposit Account
Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name: Stacy Landry, Reg. No. 42,779, Quine Intellectual Property Law Group, P.C.

Signature:

Date: January 27, 2010

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Sarah Jeromin	Date	January 27, 2010
Signature			

Applicant Initiated Interview Request Form

Application No.: 10/768,744 First Named Applicant: Christopher A. Hunter
 Examiner: Cherie Michelle Woodward Art Unit: 1647 Status of Application: _____

Tentative Participants:
 (1) Stacy Landry (2) Christopher A. Hunter
 (3) Cherie Michelle Woodward (4) Gary Nickol

Proposed Date of Interview: February 2, 2010 Proposed Time: 12:00 PM (AM/PM)
 (Eastern Standard Time)

Type of Interview Requested:
 (1) Telephonic (2) Personal (3) Video Conference

Exhibit To Be Shown or Demonstrated: YES NO
 If yes, provide brief description: _____


Issues To Be Discussed

Issues (Rej., Obj., etc)	Claims/ Fig. #s	Prior Art	Discussed	Agreed	Not Agreed
(1) Priority Claim	All pending	<u>Villarino</u>	[]	[]	[]
(2) 102 Rejections	All pending	All cited art	[]	[]	[]
(3) State of the art	All pending	Summary attached	[]	[]	[]
(4) _____	_____	_____	[]	[]	[]
<input checked="" type="checkbox"/> Continuation Sheet Attached					

Brief Description of Arguments to be Presented:
 Please see continuation sheet, which is attached.

An interview was conducted on the above-identified application on _____.
 NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview
 (see MPEP § 713.01).

This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.


Stacy Landry
 Applicant/Applicant's Representative Signature

Examiner/SPE Signature

Typed/Printed Name of Applicant or Representative
42,779

Registration Number, if applicable

This collection of information is required by 37 CFR 1.133. The information is required to obtain or retain a benefit by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the amount of time you require to complete this form and/or suggestions for reducing burden. If you require additional information on the amount of time you require to complete this form and/or suggestions for reducing burden, should be sent to US Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR C
 TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
 If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Brief Description of Arguments to be Presented:

- (1) Applicants priority document cannot be completely disregarded as a priority document and then be used as extrinsic evidence against Applicants to show the state of the art at the time of the invention.
- (2) The cited art does not teach using an IL-27R agonist for immune suppression. The cited art teaches using IL-27R agonists for immune activation. The cited art teaches generally that agonists and antagonists of cytokines can be used to modulate the immune system. It does not teach the particular species claimed.
- (3) The state of the art at the time of the invention clearly shows that Applicants invention was, at the time, a novel and surprising use for an IL-27R agonist. In fact, what one of skill in the art at the time of the invention believed was exactly opposite to what is claimed.

Draft Summary of IL-27 Art
To aid in preparation for interview

The following is a narrative that outlines the critical publications that first described the role of the IL-27R (WSX-1/TCCR) in promoting inflammation, the description of IL-27 (composed of p28 and EBI3) and the initial description of the EBI3 KO mice. Also included are references from independent sources that summarize the consensus at various times on the biology of IL-27.

1. The IL-27R (WSX-1) cloned and identified as a type I cytokine receptor and postulated to have a role in the immune system (1).
2. EBI3 cloned (2), proposed to form a heterodimer with IL-12 p35 (3) (to form what is now known as IL-35) and knocked out (4). Mice were reported to be resistant to oxazolone induced colitis and had reduced production of TH1 (IFN- γ) and TH2 (IL-4) cytokines. Also reported that they had a developmental defect in invariant NKT cells – and this was suggested to provide an explanation for the lack of disease as these iNKT cells contribute to this model of oxazalone-induced inflammation. These data provided really the first indication that EBI3 was required for inflammatory responses.
3. The first KO of the IL-27R is reported by a research group from Genentech headed by Fred Desauvage and which contained Nico Ghilardini (5). In this manuscript they presented data that the TCCR (IL-27R) deficient mice had a defect in the ability to produce IFN and consistent with this observation these mice were more susceptible to infection with Listeria. This led the authors to conclude that their “results demonstrate the existence of a new cytokine receptor involved in regulating the adaptive immune response and critical to the generation of a Th1 response”.

The apparent specificity of the phenotype described here makes TCCR and its potential ligand candidate targets for therapeutic intervention in Th1-mediated autoimmune disease and allograft rejection.

4. Studies from Hiroki Yoshida in the laboratory of Tak Mak in Toronto were published in Immunity in 2001 and showed that WSX-1 (IL-27R) KO mice were more susceptible to infection with the parasite Leishmania (6). These data were consistent with reduced production of IFN- γ in these mice and the authors concluded that “WSX-1 is essential for the initial mounting of Th1 responses”
5. In 2002, studies from the laboratory of Robert Kastlein at DNAX revealed that WSX-1 was a receptor for a novel cytokine composed of p28 and EBI3 which they called IL-27 (7). In that manuscript they showed that IL-27 could promote the production of IFN- γ from NK and T cells.
6. At this point, a consensus was emerging that IL-27, and signaling through its receptor, was an important step in the generation of Th1 responses. This idea is highlighted in

several reviews that were published at the time by independent experts in the field. For example Robinson and O'Garra (8) concluded that "IL-27 appears to act at an early stage in Th1 development in a manner distinct from IL-12". In that same year, two leading experts in the field of T cell differentiation Ken Murphy and Steve Reiner summarized the state of the field in their review article in *Nature Reviews Immunology*(9). In that review they have a section devoted to "Recently discovered Th1-cell-promoting factors" and highlight the role of IL-27 in these events and in Figure 8 of that article clearly place IL-27 as a factor that promotes the early differentiation of Th1 cells. Similarly Brombacher and colleagues in a review article concluded that "IL-27 is involved in early Th1 initiation" (10). In 2003 there were three additional publications that reinforced the concept that IL-27 promoted TH1 responses from the groups at Genentech, DNAX and Hiroki Yoshida (11-13). Articles in 2004/2005 (14, 15) continued to highlight the ability of IL-27 to promote the production of IFN- γ without mention its anti-inflammatory effects.

7. Based on this literature the blockade of the IL-27R would lead to reduced Th1 responses and that enhanced signaling through the IL-27R would lead to increased Th1 responses. In other words, these studies implicitly implied that neutralization of IL-27 or its receptor would be a viable strategy to prevent or ameliorate pathology caused by Th1 type responses, for instance in the setting of autoimmunity or transplantation. Alternatively, they implied that using IL-27 or promoting signaling through its receptor could be used to augment inflammatory responses; for example during vaccination or cancer therapy.

8. In 2002 we obtained the IL-27R deficient mice from Amgen to determine if the IL-27R was required for the development of protective immunity to the pathogen *Toxoplasma gondii*. Immunity to this organism is dependent on the ability to produce IFN- γ and based on the then existing dogma, we postulated that in the absence of the IL-27R that mice would be unable to mount a protective inflammatory response characterized by the production of IFN- γ . Our studies with the IL-27R KO mice demonstrated that, contrary to all expectations, when infected with *T. gondii* they developed a hyper-inflammatory response characterized by excessive production of IFN- γ (and other cytokines) and that the CD4+ T cells in these mice mediated disease. These studies were published in *Immunity* in late 2003(16) almost a year after the initial patent disclosure. These studies were accompanied by a manuscript from our collaborator, Hiroki Yoshida, that reached a similar conclusion with a different pathogen (17).

9. The finding that the IL-27R was in fact required to dampen inflammatory responses was regarded as extremely novel and was highlighted in an accompanying commentary article(18), by authors associated with Schering Plough/DNAX. In that article they noted that "These data suggest that IL-27 not only is dispensable for the generation of Th1 responses in strongly polarizing conditions, but, likely due to its ability to activate STAT1 and 3, also exerts a powerful negative feedback mechanism that limits T cell hyperactivity and IFN- γ production."

10. In contrast to the dogma at the time, the finding that the IL-27R was required to limit immune hyperactivity implied that IL-27 or promoting signaling through the IL-27R would be a useful way to turn off inflammation. Alternatively, the neutralization of IL-27 or blocking signaling through the IL-27R might be a useful way to augment immune responses. These key conclusions are the exact opposite of the conclusions provided in 7 above. Subsequent studies since 2004 have provided ample independent examples of situations where IL-27 is a potent antagonist of inflammatory responses(19-26). Rather than listing all of these examples there are multiple reviews and commentaries that highlight the anti-inflammatory properties of IL-27 and its potential use as a therapeutic to block inflammation (27-35).

11. We do not disagree with the initial conclusion that, under certain circumstances, IL-27 may promote inflammatory responses and there is an established literature on this facet of IL-27 biology. Rather, we would contend that the observation that the IL-27R was actually a potent inhibitor of inflammation was unexpected and would not have been predicted based on the pre-existing literature in 2003.

1. Sprecher, C. A., F. J. Grant, J. W. Baumgartner, S. R. Presnell, S. K. Schrader, T. Yamagawa, T. E. Whitmore, P. J. O'Hara, and D. F. Foster. 1998. Cloning and characterization of a novel class I cytokine receptor. *Biochem Biophys Res Commun* 246:82-90.
2. Devergne, O., M. Hummel, H. Koeppen, M. M. Le Beau, E. C. Nathson, E. Kieff, and M. Birkenbach. 1996. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. *Journal Virology* 70:1143-1153.
3. Devergne, O., M. Birkenbach, and E. Kieff. 1997. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. *Proceedings National Academy Science USA* 94:12041-12046.
4. Nieuwenhuis, E. E., M. F. Neurath, N. Corazza, H. Iijima, J. Trgovcich, S. Wirtz, J. Glickman, D. Bailey, M. Yoshida, P. R. Galle, M. Kronenberg, M. Birkenbach, and R. S. Blumberg. 2002. Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice. *Proceedings National Academy Science USA* 99:16951-16956.
5. Chen, Q., N. Ghilardi, H. Wang, T. Baker, M. H. Xie, A. Gurney, I. S. Grewal, and F. J. de Sauvage. 2000. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. *Nature* 407:916-920.
6. Yoshida, H., S. Hamano, G. Senaldi, T. Covey, R. Faggioni, S. Mu, M. Xia, A. C. Wakeham, H. Nishina, J. Potter, C. J. Saris, and T. W. Mak. 2001. WSX-1 is required for the initiation of Th1 responses and resistance to *L. major* infection. *Immunity* 15:569-578.
7. Pflanz, S., Timans, J. C., Cheung, J., Rosales, R., Kanzler, H., Gilbert, J., Hibbert, L., Churakova, T., Travis, M., Vaisberg, E., Blumenschein, W. M., Mattson, J. D., Wagner, J. L., To, W., Zurawski, S., McClanahan, T. K., Gorman, D. M., Bazan, J. F., de Waal Malefyt, R., Rennick, D., Kastelein, R. A. 2002. IL-27, a

- heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. *Immunity* 16:779-790.
- 8. Robinson, D. S., and A. O'Garra. 2002. Further checkpoints in Th1 development. *Immunity* 16:755-758.
 - 9. Murphy, K. M., and S. L. Reiner. 2002. The lineage decisions of helper T cells. *Nature Reviews Immunology* 2:933-944.
 - 10. Brombacher, F., R. A. Kastlein, and G. Alber. 2003. Novel IL-12 family members shed light on the orchestration of Th1 responses. *Trends Immunol* 24:207-212.
 - 11. Hibbert, L., S. Pflanz, R. De Waal Malefyt, and R. A. Kastlein. 2003. IL-27 and IFN- α signal via Stat1 and Stat3 and induce T-Bet and IL-12R β 2 in naive T cells. *Journal Interferon Cytokine Research* 23:513-522.
 - 12. Lucas, S., N. Ghilardi, J. Li, and F. J. de Sauvage. 2003. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. *Proc Natl Acad Sci U S A* 100:15047-15052.
 - 13. Takeda, A., S. Hamano, A. Yamanaka, T. Hanada, T. Ishibashi, T. W. Mak, A. Yoshimura, and H. Yoshida. 2003. Cutting edge: Role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. *Journal Immunology* 170:4886-4890.
 - 14. Vandenbroucke, K., I. Alloza, M. Gadina, and P. Matthys. 2004. Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. *J Pharm Pharmacol* 56:145-160.
 - 15. Becker, C., S. Wirtz, and M. F. Neurath. 2005. Stepwise regulation of TH1 responses in autoimmunity: IL-12-related cytokines and their receptors. *Inflamm Bowel Dis* 11:755-764.
 - 16. Villarino, A., L. Hibbert, L. Lieberman, E. Wilson, T. Mak, H. Yoshida, R. A. Kastlein, C. Saris, and C. A. Hunter. 2003. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. *Immunity* 19:645-655.
 - 17. Hamano, S., K. Himeno, Y. Miyazaki, K. Ishii, A. Yamanaka, A. Takeda, M. Zhang, H. Hisaeda, T. W. Mak, A. Yoshimura, and H. Yoshida. 2003. WSX-1 is required for resistance to *Trypanosoma cruzi* infection by regulation of proinflammatory cytokine production. *Immunity* 19:657-667.
 - 18. Trinchieri, G., S. Pflanz, and R. A. Kastlein. 2003. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. *Immunity* 19:641-644.
 - 19. Niedbala, W., B. Cai, X. Wei, A. Patakas, B. P. Leung, I. B. McInnes, and F. Y. Liew. 2008. Interleukin-27 attenuates collagen-induced arthritis. *Ann Rheum Dis*.
 - 20. Diveu, C., M. J. McGeachy, K. Boniface, J. S. Sturmhofer, M. Sathe, B. Joyce-Shaikh, Y. Chen, C. M. Tato, T. K. McClanahan, R. de Waal Malefyt, C. A. Hunter, D. J. Cua, and R. A. Kastlein. 2009. IL-27 blocks RORC expression to inhibit lineage commitment of Th17 cells. *J Immunol* 182:5748-5756.
 - 21. Fitzgerald, D. C., B. Cirim, T. Touil, H. Harle, J. Grammatikopoulou, J. Das Sarma, B. Gran, G. X. Zhang, and A. Rostami. 2007. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. *J Immunol* 179:3268-3275.

22. Fitzgerald, D. C., G. X. Zhang, M. El-Behi, Z. Fonseca-Kelly, H. Li, S. Yu, C. J. Saris, B. Gran, B. Ceric, and A. Rostami. 2007. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. *Nat Immunol* 8:1372-1379.
23. Miyazaki, Y., Y. Shimano, S. Wang, and H. Yoshida. 2008. Amelioration of delayed-type hypersensitivity responses by IL-27 administration. *Biochem Biophys Res Commun* 373:397-402.
24. Guo, B., E. Y. Chang, and G. Cheng. 2008. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. *J Clin Invest* 118:1680-1690.
25. Batten, M., J. Li, S. Yi, N. M. Kljavin, D. M. Danilenko, S. Lucas, J. Lee, F. J. de Sauvage, and N. Ghilardi. 2006. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. *Nat Immunol* 7:929-936.
26. Shimizu, S., N. Sugiyama, K. Masutani, A. Sadanaga, Y. Miyazaki, Y. Inoue, M. Akahoshi, R. Katafuchi, H. Hirakata, M. Harada, S. Hamano, H. Nakashima, and H. Yoshida. 2005. Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1). *J Immunol* 175:7185-7192.
27. Hunter, C. A. 2005. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. *Nat Rev Immunol* 5:521-531.
28. Batten, M., and N. Ghilardi. 2007. The biology and therapeutic potential of interleukin 27. *J Mol Med*.
29. Kastelein, R. A., C. A. Hunter, and D. J. Cua. 2007. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. *Annu Rev Immunol* 25:221-242.
30. Goriely, S., and M. Goldman. 2007. The interleukin-12 family: new players in transplantation immunity? *Am J Transplant* 7:278-284.
31. Diveu, C., M. J. McGeachy, and D. J. Cua. 2008. Cytokines that regulate autoimmunity. *Curr Opin Immunol* 20:663-668.
32. Yoshida, H., and Y. Miyazaki. 2008. Regulation of immune responses by interleukin-27. *Immunol Rev* 226:234-247.
33. Fitzgerald, D. C., and A. Rostami. 2009. Therapeutic potential of IL-27 in multiple sclerosis? *Expert Opin Biol Ther* 9:149-160.
34. Yoshida, H., M. Nakaya, and Y. Miyazaki. 2009. Interleukin 27: a double-edged sword for offense and defense. *J Leukoc Biol* 86:1295-1303.
35. Gabay, C., and I. B. McInnes. 2009. The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases. *Arthritis Res Ther* 11:230.